TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33633029

Group type: EXPERIMENTAL
Intervention: Initial surgical interventions
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pure germinoma tumors (PG)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nongerminomatous germ cell tumors (NGGCT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Treatment-related toxicity
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 34
Study: 33633114

Group type: EXPERIMENTAL
Intervention: Lentivirus-mediated gene therapy
Number of subjects: 5
Study: 33633187

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lactate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lipid peroxide (PerOx)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Total thiols
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Total plasma antioxidant capacity (TAC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oxidised LDL (oxLDL)
Number of subjects: 32
Study: 33633498

Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention over 16 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention
Number of subjects: 0
Study: 33633648

Group type: EXPERIMENTAL
Intervention: Serious game platform for Home-Based Telerehabilitation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Typically developing individuals (control group)
Number of subjects: 22
Study: 33633656

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homotaurine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 0
Study: 33633977

Group type: EXPERIMENTAL
Intervention: One-stage direct-to-implant technique using acellular dermal matrix (ADM)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Two-stage expander-to-implant technique
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 33634616

Group type: EXPERIMENTAL
Intervention: 0.8% HA gel
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group 2 (no gel)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group 1 (excipient-based gel)
Number of subjects: 61
Study: 33634729

Group type: EXPERIMENTAL
Intervention: KTE-X19
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KTE-X19 vs SoC
Number of subjects: 0
Study: 33634772

Group type: EXPERIMENTAL
Intervention: Higher Healthy Lifestyle Score (HLS)
Number of subjects: 2981
Study: 33635141

Group type: EXPERIMENTAL
Intervention: Ibudilast 100 mg/day
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 33635276

Group type: EXPERIMENTAL
Intervention: Mobile sleep hygiene advice (n=30)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Mobile sleep hygiene advice and sleep and alcohol diary self-monitoring (n=30)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Mobile sleep hygiene advice, sleep and alcohol diary self-monitoring, and sleep and alcohol data feedback (n=60)
Number of subjects: 110
Study: 33635333

Group type: EXPERIMENTAL
Intervention: sirolimus and MMF following PTCy
Number of subjects: 32
Study: 33635374

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33636137

Group type: EXPERIMENTAL
Intervention: High minority enrollment
Number of subjects: 4184

Group type: EXPERIMENTAL
Intervention: High female enrollment
Number of subjects: 4184
Study: 33636389

Group type: EXPERIMENTAL
Intervention: Plasma neurofilament light chain (NfL) measurements
Number of subjects: 62
Study: 33636454

Group type: EXPERIMENTAL
Intervention: Inhaled Azacitidine (15, 30, and 45 mg/m daily on days 1-5 and 15-19 of 28-day cycles)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled Azacitidine (higher doses)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled Azacitidine (pre- and post-treatment bronchoscopy)
Number of subjects: 8
Study: 33636843

Group type: EXPERIMENTAL
Intervention: Measured GFR
Number of subjects: 96
Study: 33636851

Group type: EXPERIMENTAL
Intervention: AlloSure® (targeted next-generation sequencing-based approach)
Number of subjects: 93
Study: 33637087

Group type: EXPERIMENTAL
Intervention: Metformin use
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Metformin initiation
Number of subjects: 510
Study: 33637216

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB) intervention, 10 sessions lasting 50 minutes each over 5 weeks
Number of subjects: 33
Study: 33638035

Group type: EXPERIMENTAL
Intervention: PIM447 250 mg QD
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: PIM447 300 mg QD
Number of subjects: 13
Study: 33638057

Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (LUS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LUS and CT correlation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Distance to pleura
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LUS findings
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Distance to pleura correlation
Number of subjects: 60
Study: 33638113

Group type: EXPERIMENTAL
Intervention: AKCEA-TTR-L
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 140
Study: 33638249

Group type: EXPERIMENTAL
Intervention: Perioperative assessment and provision of perioperative support
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Qualitative semi-structured interviews
Number of subjects: 120
Study: 33638263

Group type: EXPERIMENTAL
Intervention: Antidepressant medication (escitalopram or duloxetine) for 8 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Treatment-naïve patients
Number of subjects: 41
Study: 33638811

Group type: EXPERIMENTAL
Intervention: Metamizole exposure
Number of subjects: 32
Study: 33638863

Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS 300 μg once daily for 29 days
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS
Number of subjects: 22
Study: 33639190

Group type: EXPERIMENTAL
Intervention: Whole-pelvis intensity-modulated radiotherapy (WPRT)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: DVH (best cut-off: V46Gy ≥80 cc)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Constrained bowel loops (V46 < 80 cc)
Number of subjects: 415
Study: 33639216

Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 139
Study: 33639518

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training with music therapy (2 sessions per week for 3 months)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study: 33639779

Group type: EXPERIMENTAL
Intervention: Total squared changes of Mel-Frequency Cepstral Coefficients (TSC_MFCC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Durational measures
Number of subjects: 0
Study: 33639900

Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells (UC-MSCs) injected intravenously at a dose of 1 × 10^6 cells/kg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard immunosuppressive therapy (IST)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells (UC-MSCs) with IST
Number of subjects: 18
Study: 33639987

Group type: EXPERIMENTAL
Intervention: Midkine inhibition via adeno-associated virus (AAV) targeting; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midkine levels in plasma and lung; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro study using inhibitors targeting candidate receptors of midkine; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 33639990

Group type: EXPERIMENTAL
Intervention: Miransertib treatment for a median duration of 22 months (range 22-28).
Number of subjects: 2
Study: 33640028

Group type: EXPERIMENTAL
Intervention: Facilitators identified include 'recognizing and addressing' by close others, 'waiting times and availability', 'recommendations and referrals' by health care professionals, and 'positive role models for treatment'.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Barriers identified include factors within the patient, social environment, health care system, and society.
Number of subjects: 22
Study: 33640346

Group type: EXPERIMENTAL
Intervention: His-optimized cardiac resynchronization therapy (HOT-CRT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Biventricular pacing (BiV)
Number of subjects: 19

Group type: COMPARATOR
Intervention: His bundle pacing (HBP)
Number of subjects: 19
Study: 33640423

Group type: EXPERIMENTAL
Intervention: Proton therapy (PT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensity modulated radiation therapy (IMRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stereotactic body proton therapy (SBPT)
Number of subjects: 0
Study: 33640521

Group type: EXPERIMENTAL
Intervention: Patient-centered opioid prescription guidelines
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Nonopioid analgesics
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: FDA-compliant disposal methods
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Convenient drop-box for disposal
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Prescribed pills
Number of subjects: 229
Study: 33640578

Group type: EXPERIMENTAL
Intervention: Pre-treatment FDG-PET and DWI-MR imaging parameters
Number of subjects: 33
Study: 33640865

Group type: EXPERIMENTAL
Intervention: Hudl Technique app with telehealth
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard HEPs on paper without feedback (control)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comparison between experimental and control groups
Number of subjects: 45
Study: 33640871

Group type: EXPERIMENTAL
Intervention: Ribociclib 300 mg three weeks in a row with a 1 week break and everolimus 2.5 mg daily (first 12 patients)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ribociclib 200 mg and everolimus 2.5 mg daily (additional 9 patients)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of ribociclib and everolimus
Number of subjects: 21
Study: 33641042

Group type: EXPERIMENTAL
Intervention: Anthracycline-based therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ifosfamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoposide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soft tissue sarcoma regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NF1-associated MPNST
Number of subjects: 0
Study: 33641083

Group type: EXPERIMENTAL
Intervention: HP (trastuzumab + pertuzumab)
Number of subjects: 948

Group type: COMPARATOR
Intervention: H without P (trastuzumab without pertuzumab)
Number of subjects: 948

Group type: COMPARATOR
Intervention: No H (no trastuzumab)
Number of subjects: 948

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 948
Study: 33641211

Group type: EXPERIMENTAL
Intervention: Ixazomib (MLN9708) 4 mg in combination with Fulvestrant
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ixazomib (MLN9708) and Fulvestrant
Number of subjects: 9
Study: 33641356

Group type: EXPERIMENTAL
Intervention: Inorganic Nitrite Supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33641372

Group type: EXPERIMENTAL
Intervention: Rotational atherectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified balloons
Number of subjects: 0
Study: 33641374

Group type: EXPERIMENTAL
Intervention: 3-Month Dual Antiplatelet Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33641385

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) performed in 49 patients (32.7%; mechanical thrombectomy, n=43)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 150
Study: 33641670

Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 41
Study: 33641678

Group type: EXPERIMENTAL
Intervention: HC-INR
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HC-ACT+
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HC-ACT-LR
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HC-aPTT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ROC curve
Number of subjects: 20
Study: 33641772

Group type: EXPERIMENTAL
Intervention: Cemiplimab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 0
Study: 33643204

Group type: EXPERIMENTAL
Intervention: Digital therapeutic for speech, language, and cognitive intervention
Number of subjects: 0
Study: 33643689

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) 6 or 8 Gy x 2 or 3 doses followed by 4 cycles of ipilimumab
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) followed by ipilimumab
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by ipilimumab
Number of subjects: 22
Study: 33643905

Group type: EXPERIMENTAL
Intervention: Endocrine Therapy (ET)
Number of subjects: 2342

Group type: COMPARATOR
Intervention: Chemotherapy (CT)
Number of subjects: 2342

Group type: EXPERIMENTAL
Intervention: Palliative ET
Number of subjects: 2342

Group type: EXPERIMENTAL
Intervention: First line ET
Number of subjects: 2342

Group type: EXPERIMENTAL
Intervention: Second line ET
Number of subjects: 2342

Group type: EXPERIMENTAL
Intervention: Third line ET
Number of subjects: 2342

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (AI) monotherapy
Number of subjects: 2342

Group type: EXPERIMENTAL
Intervention: Everolimus plus AI regimen
Number of subjects: 2342
Study: 33643965

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 33644082

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo or standard care)
Number of subjects: 0
Study: 33644099

Group type: EXPERIMENTAL
Intervention: Furin expression levels in patients with psoriasis
Number of subjects: 0
Study: 33644235

Group type: EXPERIMENTAL
Intervention: IgG quantification against S1-RBD of SARS-CoV-2
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Neutralizing antibody quantification using ELISA and luminescent SARS-CoV-2 pseudotype
Number of subjects: 639
Study: 33644492

Group type: EXPERIMENTAL
Intervention: Electronic monitoring devices (EMDs) linked to a mobile application (app) for ICS and rescue inhalers
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard of care (controls)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Electronic monitoring devices (EMDs)
Number of subjects: 75
Study: 33644749

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study: 33644759

Group type: COMPARATOR
Intervention: Calorie restriction (CR)
Number of subjects: 0
Study: 33644812

Group type: EXPERIMENTAL
Intervention: Handgrip force
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MIP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MEP
Number of subjects: 20
Study: 33645542

Group type: EXPERIMENTAL
Intervention: PLD1 variants
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PLD1 inhibition
Number of subjects: 30
Study: 33646153

Group type: EXPERIMENTAL
Intervention: UPSIT (University of Pennsylvania Smell Identification Test)
Number of subjects: 54
Study: 33646302

Group type: EXPERIMENTAL
Intervention: HLA-haploidentical HSCT with age-adapted myeloablative conditioning and T-cell immunotherapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HLA-haploidentical HSCT
Number of subjects: 50
Study: 33646505

Group type: EXPERIMENTAL
Intervention: Olfactory and gustatory dysfunctions (OGD)
Number of subjects: 5868
Study: 33646820

Group type: EXPERIMENTAL
Intervention: Entrectinib
Number of subjects: 161
Study: 33647009

Group type: EXPERIMENTAL
Intervention: Infection Manager System (IMS)
Number of subjects: 914

Group type: COMPARATOR
Intervention: C-reactive protein (CRP) at ≥20mg/L
Number of subjects: 914

Group type: COMPARATOR
Intervention: Procalcitonin (PCT) at 0.5 ng/ml
Number of subjects: 914
Study: 33647286

Group type: EXPERIMENTAL
Intervention: EUS-guided verteporfin photodynamic therapy (PDT) at a dosage of 0.4 mg/kg infused 60 to 90 minutes before EUS, with light delivered at 50 J/cm for 333 seconds
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: EUS-guided verteporfin photodynamic therapy (PDT)
Number of subjects: 8
Study: 33647333

Group type: COMPARATOR
Intervention: Electroencephalogram (EEG) frequency bands: SMR (12-15 Hz), beta (14.5-30 Hz), beta I (14.5-20 Hz), beta II (20-25 Hz), beta III (25-30 Hz), gamma I (31-49 Hz)
Number of subjects: 402
Study: 33647530

Group type: EXPERIMENTAL
Intervention: HABIT-ILE (hand-arm bimanual intensive therapy including lower extremities)
Number of subjects: 25
Study: 33647548

Group type: EXPERIMENTAL
Intervention: Initial irinotecan (Arm B)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Sequential irinotecan (Arm A)
Number of subjects: 421
Study: 33647913

Group type: COMPARATOR
Intervention: Renal Autologous Cell Therapy (REACT); 2 doses at 6-month intervals
Number of subjects: 5
Study: 33647987

Group type: EXPERIMENTAL
Intervention: Monopolar hypoglossal nerve stimulation (HNS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guarded bipolar hypoglossal nerve stimulation (HNS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grouped cathode and single cathode configurations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monopolar configurations
Number of subjects: 0
Study: 33648577

Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine solution
Number of subjects: 135

Group type: COMPARATOR
Intervention: 4% chlorhexidine gluconate solution
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 135
Study: 33649057

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention: 3 weekly face-to-face consultations between dyads and trained nurses.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention: 3 biweekly educational sessions between dyads and trained physiotherapists focused on self-management, goal-setting, physical activity with three home exercise sessions per week.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Psychoeducational and rehabilitative intervention combined.
Number of subjects: 30
Study: 33649343

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3500
Study: 33649760

Group type: EXPERIMENTAL
Intervention: Regular plasma prophylaxis
Number of subjects: 87

Group type: COMPARATOR
Intervention: No regular plasma prophylaxis
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Children <10 years of age
Number of subjects: 87

Group type: COMPARATOR
Intervention: Patients >40 years of age
Number of subjects: 87
Study: 33650179

Group type: EXPERIMENTAL
Intervention: Weekly carfilzomib (20/70 mg/m²), cyclophosphamide, and dexamethasone (wKCd)
Number of subjects: 0
Study: 33650259

Group type: EXPERIMENTAL
Intervention: Real-world data (RWD) from NHANES and longitudinal data from elagolix phase III clinical trials
Number of subjects: 0
Study: 33650294

Group type: EXPERIMENTAL
Intervention: Etonogestrel pharmacokinetic and pharmacodynamic outcomes based on genetic ancestry (EUR, AFR, AMR)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Serum etonogestrel concentrations
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Progestin-related side effects (bothersome bleeding and subjective weight gain)
Number of subjects: 350
Study: 33650449

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33650781

Group type: EXPERIMENTAL
Intervention: Single bout of moderate-intensity exercise (treadmill walking, expending 500 kcal at 60%-70% VO2 max)
Number of subjects: 42
Study: 33650967

Group type: EXPERIMENTAL
Intervention: TLR7 deleterious variants in severely affected males (2.1%)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Functional gene expression profile analysis
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: TLR7 loss-of-function variants
Number of subjects: 156
Study: 33650972

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy
Number of subjects: 19
Study: 33650998

Group type: EXPERIMENTAL
Intervention: Deceased donor liver transplantation (DDLT) for patients with HCC and hilar CCA (hCCA) with an exception score of median MELD score at transplant (MMAT)-3.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deceased donor liver transplantation (DDLT) and living donor liver transplantation (LDLT) for iCCA and CRLM.
Number of subjects: 0
Study: 33651116

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 37 MBq (± 10%)
Number of subjects: 10
Study: 33651243

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion with conversation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Remifentanil infusion in a quiet environment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 0
Study: 33651368

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 363919

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 363919

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 363919

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 363919
Study: 33651630

Group type: EXPERIMENTAL
Intervention: Training overload (TO) phase for 4 weeks followed by a 2-week recovery, with running volume at 131 ± 3% of baseline during TO and 63 ± 6% during recovery.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Well-adapted (WA) runners (control group).
Number of subjects: 16
Study: 33651744

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: RFM
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: WC
Number of subjects: 277
Study: 33652270

Group type: EXPERIMENTAL
Intervention: Ketamine anesthesia
Number of subjects: 11

Group type: COMPARATOR
Intervention: Etomidate anesthesia
Number of subjects: 11